ACP-001

ACP-001 refers to at least two distinct investigational therapies in clinical development, each by different companies and for different indications: 1. **Ascendis Pharma's ACP-001** is a proprietary once-weekly human growth hormone (hGH) prodrug designed to treat growth hormone deficiency in children and adults. It releases unmodified hGH in a controlled manner, aiming to improve patient compliance compared to daily injections. The drug has demonstrated safety and efficacy in Phase 1 studies, with ongoing Phase 2 trials evaluating its pharmacokinetics, pharmacodynamics, safety, and tolerability[7][9]. 2. **XNK Therapeutics' ACP-001** is an autologous natural killer (NK) cell therapy developed for the treatment of multiple myeloma as consolidation after high-dose autologous stem cell transplantation. This cell therapy leverages immunologic cytotoxicity via NK cells to target cancer cells. Early-phase clinical trials have shown promising safety results and measurable responses in patients[3][4]. Because both drugs share the code name "ACP-001" but are unrelated products from different developers with distinct mechanisms of action and indications, all relevant details are provided below.